What’s in Xbiotech Inc (NASDAQ:XBIT) After Rise in Shorted Shares?

XBiotech Inc. (NASDAQ:XBIT) Logo

The stock of Xbiotech Inc (NASDAQ:XBIT) registered an increase of 13.94% in short interest. XBIT’s total short interest was 1.25 million shares in March as published by FINRA. Its up 13.94% from 1.10 million shares, reported previously. With 293,500 shares average volume, it will take short sellers 4 days to cover their XBIT’s short positions. The short interest to Xbiotech Inc’s float is 6.24%.

The stock decreased 0.70% or $0.07 during the last trading session, reaching $9.98. About 104,516 shares traded. XBiotech Inc. (NASDAQ:XBIT) has risen 90.53% since March 13, 2018 and is uptrending. It has outperformed by 86.16% the S&P500.

XBiotech Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing True Human monoclonal antibodies for treating various diseases. The company has market cap of $357.48 million. The company??s lead product is Xilonix, which is also known as MABp1, a therapeutic antibody that neutralizes interleukin-1 alpha, which has completed Phase III clinical trial in Europe for the treatment of symptomatic and advanced colorectal cancer. It currently has negative earnings. It has also investigating its lead product candidate in various clinical trials for other inflammatory conditions, including vascular disease, type II diabetes, acne, psoriasis, pyoderma gangrenosum, and hidradenitis suppurativa, as well as staphylococcus aureus infection, influenza, and clostridium difficile infection diseases.

More important recent XBiotech Inc. (NASDAQ:XBIT) news were published by: Seekingalpha.com which released: “XBiotech up 13% on positive bermekimab data – Seeking Alpha” on March 01, 2019, also Seekingalpha.com published article titled: “XBiotech up 4% premarket on positive bermekimab data – Seeking Alpha”, Streetinsider.com published: “XBiotech (XBIT) Says Results from Phase 2 Clinical Trial of Bermekimab in Treatment of Atopic Dermatitis to be Presented at ADD – StreetInsider.com” on March 01, 2019. More interesting news about XBiotech Inc. (NASDAQ:XBIT) was released by: Seekingalpha.com and their article: “Key events next week – healthcare – Seeking Alpha” with publication date: February 22, 2019.

Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.



Source link

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply

Your email address will not be published. Required fields are marked *